<DOC>
	<DOCNO>NCT01383161</DOCNO>
	<brief_summary>This project design study effect dietary supplement curcumin age-related cognitive impairment . In particular , study seek determine effect curcumin cognitive decline amount abnormal amyloid protein brain . Genetic risk also study potential predictor cognitive decline . Subjects randomly assign one two treatment group : either placebo curcumin supplement ( 465 milligram Theracurminâ„¢ 30 mg curcumin ) . The investigator expect people receive curcumin supplement show less evidence decline few 18 month receive placebo . The investigator believe cognitive decline treatment response vary accord genetic risk Alzheimer 's . The investigator study 132 subject memory complaint age 50-90 year . Initially , subject undergo clinical assessment , MRI blood draw determine genetic risk rule neurodegenerative disorder link memory complaint . Subsequently , subject undergo - ( 1- { 6- [ ( 2- [ F-18 ] fluoroethyl ) ( methyl ) amino ] -2-naphthyl } ethylidene ) malononitrile ( FDDNP ) PET scan baseline neuropsychological assessment confirm MCI normal age diagnosis . Once enrol , subject begin take supplement ( either curcumin placebo ) , ask return every three month regular MRIs review session . Every 6 month , subject also neuropsychological assessment . At conclusion study , subject ask complete final neuropsychological assessment , MRI scan , PET scan blood draw . Additional blood drawn baseline 18 month frozen assess inflammatory marker outcomes positive . FDDNP-PET scan use measure amount abnormal amyloid plaque- tau tangle- protein brain ; MRIs use monitor supplement side effect measure brain structure ; neuropsychological assessment monitor rate cognitive decline ; blood draw use test level inflammatory marker .</brief_summary>
	<brief_title>18-Month Study Curcumin</brief_title>
	<detailed_description>Several line evidence suggest neuropathological clinical decline lead Alzheimer disease ( AD ) begin year patient develop full AD clinical syndrome ( NINCDS-ADRDA diagnostic criterion ; McKhann et al , 1984 ) . Mild memory complaint build gradually year patient develop dementia . The neuropathological hallmark AD , `` preclinical '' neuritic plaque ( Braak &amp; Braak , 1991 ) neurofibrillary tangle ( Price &amp; Morris , 1999 ) , also present year prior clinical diagnosis . These abnormal protein deposit correlate strongly cognitive decline . Preclinical amyloid deposit may begin decade prior dementia onset . In fact , diffuse plaque non-demented elderly person associate accelerate age-related cortical cholinergic deficit , consistent preclinical AD ( Beach et al , 1997 ; Arai et al , 1999 ) . Also consistent prolong preclinical disease stage work show position emission tomography ( PET ) measure cerebral glucose metabolism vary accord AD genetic risk ( apolipoprotein E-4 [ APOE-4 ] ) predict cerebral metabolic cognitive decline people mild cognitive complaint ( age-associated memory impairment [ AAMI ] ; Small et al , 2000 ) . Such observation stimulate interest preclinical AD marker biomarkers brain aging may assist track treatment AAMI related condition . New PET image method make possible provide vivo measure cerebral amyloid neuritic plaque ( e.g. , florbetapir-PET ; Clarke et al , 2011 ) tau neurofibrillary tangle ( e.g . FDDNP-PET ; Small et al , 2006 , 2009 ) . Despite previous research finding , clinical trial ( include use biomarkers response measure ) subsequent treatment recommendation limit patient full clinical dementia syndrome mild cognitive impairment ( MCI ) , condition increase risk develop dementia ( Petersen et al , 2001 ) . Cholinesterase inhibitor currently drug FDA clearance treatment AD , previous study ( e.g. , Ringman et al , 2005 ) suggest intervention , dietary herbal supplement , may benefit cognition , possibly interrupt accumulation abnormal amyloid protein deposit brain . For example , curcumin ( diferulomethane ) , low molecular weight molecule antioxidant anti-inflammatory activity derive dietary spice , may cognitive-enhancing anti-amyloid property ( Ringman et al , 2005 ; Yang et al , 2005 ) . To address issue , propose build upon group 's previous longitudinal brain imaging genetic risk study people age-related memory decline . Because previous study suggest curcumin may improve cognitive ability prevent build-up age-associated plaque tangle brain , perform double-blind , placebo-controlled trial curcumin test follow hypothesis : 1 . People age-related cognitive decline ( i.e. , MCI , AAMI normal age ) , , receive curcumin 90 mg twice day show less evidence cognitive decline ( measured neuropsychological assessment ) receive placebo 18 month . 2 . People age-related cognitive decline receive oral dose curcumin 90 mg twice day show less build-up plaque tangle ( measure FDDNP-PET image ) receive placebo 18 month . 3 . People age-related cognitive decline , receive curcumin 90 mg twice day , show decreased measure inflammation blood compare receive placebo 18 month . 4 . Cognitive change , FDDNP-PET measure , treatment response vary accord genotype find influence age dementia onset ( e.g. , apolipoprotein E [ APOE ] TOMM40 ) . Because curcumin may alter inflammatory marker blood , draw blood sample baseline 18 month freeze later analyse . To test thesis hypothesis , 132 subject , age-related cognitive decline enrol ( Crook et al , 1986 ; Petersen et al , 2001 ) . Subjects randomize , use double-blind design , one two treatment group : curcumin ( three 30 mg capsule twice day ) placebo , follow 18 month . FDDNP-PET scanning perform baseline 18 month . Magnetic resonance imaging ( MRI ) scan also perform co-registration PET assistance identify region interest . Neuropsychological assessment perform baseline , 6 month , 12 month conclusion clinical trial ( 18 month ) . Blood drawn baseline perform genotyping .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Inclusion Criteria 1 . Agreement participate 18month doubleblind , placebocontrolled clinical trial curcumin . 2 . Diagnostic criterion mild cognitive impairment ( MCI ) age related memory decline accord standard criterion ( Petersen et al , 2001 ; Crook et al , 1986 ) . 3 . Age 50 90 year . 4 . No significant cerebrovascular disease : modify Ischemic Score &lt; 4 ( Rosen et al , 1980 ) . 5 . Adequate visual auditory acuity allow neuropsychological testing . 6 . Screening laboratory test EKG without significant abnormality might interfere study . Exclusion Criteria 1 . Diagnosis probable Alzheimer 's disease ( AD ) dementia ( e.g. , vascular , Lewy body , frontotemporal ) ( McKhann et al , 1984 ) . 2 . Evidence neurological physical illness produce cognitive deterioration . Volunteers history stroke , TIA , carotid bruits , lacunes MRI scan exclude . 3 . Inability undergo MRI . 4 . Evidence Parkinson 's disease determine motor examination ( item 1831 ) Unified Parkinson 's Disease Rating Scale ( Fahn et al , 1987 ) . 5 . History myocardial infarction within previous year , unstable cardiac disease . 6 . Uncontrolled hypertension ( systolic BP &gt; 170 diastolic BP &gt; 100 ) . 7 . History significant liver disease , clinicallysignificant pulmonary disease , diabetes , cancer . 8 . Current diagnosis major psychiatric disorder accord DSMIV TR criterion ( APA , 2000 ) . 9 . Current diagnosis history alcoholism substance addiction . 10 . Regular use medication may affect cognitive function include : centrally active betablockers , narcotic , Clonidine , antiParkinsonian medication , antipsychotic , benzodiazepine , systemic corticosteroid , medication significant cholinergic anticholinergic effect , anticonvulsant , Warfarin . Occasional chloral hydrate use allow , discourage , insomnia . 11 . Use one multivitamin per day . Vitamins standard multivitamin supplement allow . 12 . Use medication know affect FDDNPPET binding ( e.g. , ibuprofen , naproxen ) . 13 . Use one daily baby aspirin ( 81mg ) and/or use medication contain curcumin . 14 . Use cognitive enhancing supplement ( e.g . Ginkgo biloba ) . 15 . Use investigational drug within previous month longer , depend drug halflife . 16 . Pregnancy . 17 . HIV infection . 18 . Evidence vasogenic edema ; specifically , evidence 4 cerebral microhemorrhages ( regardless anatomical location diagnostic characterization `` possible '' `` definite '' ) single area superficial siderosis ) , evidence prior macrohemorrhage screen baseline .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Curcumin</keyword>
	<keyword>Turmeric</keyword>
	<keyword>Memory</keyword>
	<keyword>Cognitive Impairment</keyword>
	<keyword>Brain Imaging</keyword>
	<keyword>Supplement</keyword>
</DOC>